{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T15:03:30Z","timestamp":1795100610251,"version":"4.10.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Following curettage of giant cell tumor of bone (GCTB), it is common to fill the cavity with polymethylmethacrylate (PMMA) bone cement, bone allograft, or artificial bone to maintain bone strength; however, there is a 2\u201314% risk of postoperative fractures. We conducted this retrospective study to clarify the risk factors for fractures after curettage for GCTB of the extremities.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study included 284 patients with GCTBs of the extremities who underwent curettage at our institutions between 1980 and 2018 after excluding patients whose cavities were not filled with anything or who had additional plate fixation. The tumor cavity was filled with PMMA bone cement alone (<jats:italic>n\u2009=<\/jats:italic>\u00a0124), PMMA bone cement and bone allograft (<jats:italic>n\u2009=<\/jats:italic>\u00a081), bone allograft alone (<jats:italic>n\u2009=<\/jats:italic>\u00a063), or hydroxyapatite graft alone (<jats:italic>n\u2009=<\/jats:italic>\u00a016).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fractures after curettage occurred in 10 (3.5%) patients, and the median time from the curettage to fracture was 3.5\u2009months (interquartile range [IQR], 1.8\u20138.3\u2009months). The median postoperative follow-up period was 86.5\u2009months (IQR, 50.3\u2013118.8\u2009months). On univariate analysis, patients who had GCTB of the proximal or distal femur (1-year fracture-free survival, 92.5%; 95% confidence interval [CI]: 85.8\u201396.2) presented a higher risk for postoperative fracture than those who had GCTB at another site (100%; <jats:italic>p<\/jats:italic>\u2009=\u20090.0005). Patients with a pathological fracture at presentation (1-year fracture-free survival, 88.2%; 95% CI: 63.2\u201397.0) presented a higher risk for postoperative fracture than those without a pathological fracture at presentation (97.8%; 95% CI: 95.1\u201399.0; <jats:italic>p<\/jats:italic>\u2009=\u20090.048). Patients who received bone grafting (1-year fracture-free survival, 99.4%; 95% CI: 95.7\u201399.9) had a lower risk of postoperative fracture than those who did not receive bone grafting (94.4%; 95% CI: 88.7\u201397.3; <jats:italic>p<\/jats:italic>\u2009=\u20090.003).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>For GCTBs of the femur, especially those with pathological fracture at presentation, bone grafting after curettage is recommended to reduce the risk of postoperative fracture. Additional plate fixation should be considered when curettage and cement filling without bone grafting are performed in patients with GCTB of the femur. This should be specially performed for those patients with a pathological fracture at presentation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12891-022-05447-x","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T11:24:43Z","timestamp":1652959483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Risk factors of fracture following curettage for bone giant cell tumors of the extremities"],"prefix":"10.1186","volume":"23","author":[{"given":"Shinji","family":"Tsukamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas F.","family":"Mavrogenis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Akahane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanya","family":"Honoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide Maria","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costantino","family":"Errani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"5447_CR1","first-page":"440","volume-title":"World Health Organ Classif Tumours Editorial Board. WHO classification of tumours","author":"AM Flanagan","year":"2020","unstructured":"Flanagan AM, Larousserie F, O\u2019Donnell PG, Yoshida A. Giant cell tumour of bone. In:  World Health Organ Classif Tumours Editorial Board. WHO classification of tumours. 5th ed: Soft Tissue and Bone Tumours. Lyon: IARC; 2020. p. 440\u20136.","edition":"5"},{"key":"5447_CR2","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s11999-016-4755-x","volume":"475","author":"J Benevenia","year":"2017","unstructured":"Benevenia J, Rivero SM, Moore J, Ippolito JA, Siegerman DA, Beebe KS, et al. Supplemental bone grafting in giant cell tumor of the extremity reduces nononcologic complications. Clin Orthop Relat Res. 2017;475:776\u201383.","journal-title":"Clin Orthop Relat Res"},{"key":"5447_CR3","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.2106\/JBJS.M.00066","volume":"95","author":"L van der Heijden","year":"2013","unstructured":"van der Heijden L, van de Sande MAJ, Heineken AC, Fiocco M, Nelissen RGHH, Dijkstra PDS. Mid-term outcome after curettage with polymethylmethacrylate for giant cell tumor around the knee: higher risk of radiographic osteoarthritis? J Bone Joint Surg Am. 2013;95:e159.","journal-title":"J Bone Joint Surg Am"},{"key":"5447_CR4","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.2106\/JBJS.M.00516","volume":"96","author":"L van der Heijden","year":"2014","unstructured":"van der Heijden L, van der Geest ICM, Schreuder HWB, van de Sande MAJ, Dijkstra PDS. Liquid nitrogen or phenolization for giant cell tumor of bone?: a comparative cohort study of various standard treatments at two tertiary referral centers. J Bone Joint Surg Am. 2014;96:e35.","journal-title":"J Bone Joint Surg Am"},{"key":"5447_CR5","doi-asserted-by":"crossref","unstructured":"Uglialoro AD, Maceroli M, Beebe KS, Benevenia J, Patterson FR. Distal femur defects reconstructed with polymethylmethacrylate and internal fixation devices: a biomechanical study. Orthopedics. 2009;32 orthosupersite.com\/view.asp?rID=41918.","DOI":"10.3928\/01477447-20090624-29"},{"key":"5447_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s10195-016-0394-y","volume":"17","author":"J Ruskin","year":"2016","unstructured":"Ruskin J, Caravaggi P, Beebe KS, Corgan S, Chen L, Yoon RS, et al. Steinmann pin augmentation versus locking plate constructs. J Orthop Traumatol. 2016;17:249\u201354.","journal-title":"J Orthop Traumatol"},{"key":"5447_CR7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/BLO.0b013e31805d85e4","volume":"459","author":"BM Deheshi","year":"2007","unstructured":"Deheshi BM, Jaffer SN, Griffin AM, Ferguson PC, Bell RS, Wunder JS. Joint salvage for pathologic fracture of giant cell tumor of the lower extremity. Clin Orthop Relat Res. 2007;459:96\u2013104.","journal-title":"Clin Orthop Relat Res"},{"key":"5447_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4103\/0019-5413.32040","volume":"41","author":"S Rastogi","year":"2007","unstructured":"Rastogi S, Prashanth I, Khan SA, Trikha V, Mittal R. Giant cell tumor of bone: is curettage the answer? Indian J Orthop. 2007;41:109\u201314.","journal-title":"Indian J Orthop"},{"key":"5447_CR9","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1302\/0301-620X.100B12.BJJ-2018-0189.R2","volume":"100\u2013B","author":"MR Medellin","year":"2018","unstructured":"Medellin MR, Fujiwara T, Tillman RM, Jeys LM, Gregory J, Stevenson JD, et al. Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture. Bone Joint J. 2018;100\u2013B:1626\u201332.","journal-title":"Bone Joint J"},{"key":"5447_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1302\/0301-620X.96B1.31763","volume":"96\u2013B","author":"AE Wijsbek","year":"2014","unstructured":"Wijsbek AE, Vazquez-Garcia BL, Grimer RJ, Carter SR, Abudu AA, Tillman RM, et al. Giant cell tumour of the proximal femur: is joint-sparing management ever successful? Bone Joint J. 2014;96\u2013B:127\u201331.","journal-title":"Bone Joint J"},{"key":"5447_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.2106\/00004623-198769010-00018","volume":"69","author":"M Campanacci","year":"1987","unstructured":"Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg Am. 1987;69:106\u201314.","journal-title":"J Bone Joint Surg Am"},{"key":"5447_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00590-019-02535-y","volume":"30","author":"S Tsukamoto","year":"2020","unstructured":"Tsukamoto S, Mavrogenis AF, Tanzi P, Leone G, Akahane M, Tanaka Y, et al. Curettage as first surgery for bone giant cell tumor: adequate surgery is more important than oncology training or surgical management by high volume specialized teams. Eur J Orthop Surg Traumatol. 2020;30:3\u20139.","journal-title":"Eur J Orthop Surg Traumatol"},{"key":"5447_CR13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3928\/01477447-20200721-03","volume":"43","author":"S Tsukamoto","year":"2020","unstructured":"Tsukamoto S, Mavrogenis AF, Tanzi P, Leone G, Ciani G, Righi A, et al. Denosumab for bone giant cell tumor of the distal radius. Orthopedics. 2020;43:284\u201391.","journal-title":"Orthopedics."},{"key":"5447_CR14","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00590-017-1983-z","volume":"27","author":"C Errani","year":"2017","unstructured":"Errani C, Tsukamoto S, Leone G, Akahane M, Cevolani L, Tanzi P, et al. Higher local recurrence rates after intralesional surgery for giant cell tumor of the proximal femur compared to other sites. Eur J Orthop Surg Traumatol. 2017;27:813\u20139.","journal-title":"Eur J Orthop Surg Traumatol"},{"key":"5447_CR15","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/jso.25391","volume":"119","author":"S Tsukamoto","year":"2019","unstructured":"Tsukamoto S, Mavrogenis AF, Tanzi P, Leone G, Righi A, Akahane M, et al. Similar local recurrence but better function with curettage versus resection for bone giant cell tumor and pathological fracture at presentation. J Surg Oncol. 2019;119:864\u201372.","journal-title":"J Surg Oncol"},{"key":"5447_CR16","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.2106\/00004623-199412000-00009","volume":"76","author":"RJ O\u2019Donnell","year":"1994","unstructured":"O\u2019Donnell RJ, Springfield DS, Motwani HK, Ready JE, Gebhardt MC, Mankin HJ. Recurrence of giant-cell tumors of the long bones after curettage and packing with cement. J Bone Joint Surg Am. 1994;76:1827\u201333.","journal-title":"J Bone Joint Surg Am"},{"key":"5447_CR17","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1007\/s11999-012-2546-6","volume":"471","author":"L van der Heijden","year":"2013","unstructured":"van der Heijden L, Dijkstra PDS, Campanacci DA, Gibbons CLMH, van de Sande MAJ. Giant cell tumor with pathologic fracture: should we curette or resect? Clin Orthop Relat Res. 2013;471:820\u20139.","journal-title":"Clin Orthop Relat Res"},{"key":"5447_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00264-017-3664-2","volume":"42","author":"DX Lun","year":"2018","unstructured":"Lun DX, Hu YC, Yang XG, Wang Z, Yu XC, Wu SJ, et al. Development and proposal of a scoring system for giant cell tumour of the bone around the knee. Int Orthop. 2018;42:203\u201313.","journal-title":"Int Orthop"},{"key":"5447_CR19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/BPO.0b013e31829b2f61","volume":"34","author":"MT Wallace","year":"2014","unstructured":"Wallace MT, Henshaw RM. Results of cement versus bone graft reconstruction after intralesional curettage of bone tumors in the skeletally immature patient. J Pediatr Orthop. 2014;34:92\u2013100.","journal-title":"J Pediatr Orthop"},{"key":"5447_CR20","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/jbm.1263","volume":"59","author":"T Hisatome","year":"2002","unstructured":"Hisatome T, Yasunaga Y, Ikuta Y, Fujimoto Y. Effects on articular cartilage of subchondral replacement with polymethylmethacrylate and calcium phosphate cement. J Biomed Mater Res. 2002;59:490\u20138.","journal-title":"J Biomed Mater Res"},{"key":"5447_CR21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/00003086-200403000-00035","volume":"420","author":"PJ Murray","year":"2004","unstructured":"Murray PJ, Damron TA, Green JK, Morgan HD, Werner FW. Contained femoral defects: biomechanical analysis of pin augmentation in cement. Clin Orthop Relat Res. 2004;420:251\u20136.","journal-title":"Clin Orthop Relat Res"},{"key":"5447_CR22","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S0736-0266(01)00124-3","volume":"20","author":"RD Welch","year":"2002","unstructured":"Welch RD, Berry BH, Crawford K, Zhang H, Zobitz M, Bronson D, et al. Subchondral defects in caprine femora augmented with in situ setting hydroxyapatite cement, polymethylmethacrylate, or autogenous bone graft: biomechanical and histomorphological analysis after two-years. J Orthop Res. 2002;20:464\u201372.","journal-title":"J Orthop Res"},{"key":"5447_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/BF00381536","volume":"100","author":"PA Manley","year":"1982","unstructured":"Manley PA, McKeown DB, Schatzker J, Palmer NC, Carman S. Replacement of epiphyseal bone with methylmethacrylate: its effect on articular cartilage. Arch Orthop Trauma Surg. 1982;100:3\u201310.","journal-title":"Arch Orthop Trauma Surg"},{"key":"5447_CR24","first-page":"378","volume":"293","author":"FJ Frassica","year":"1993","unstructured":"Frassica FJ, Gorski JP, Pritchard DJ, Sim FH, Chao EY. A comparative analysis of subchondral replacement with polymethylmethacrylate or autogenous bone grafts in dogs. Clin Orthop Relat Res. 1993;293:378\u201390.","journal-title":"Clin Orthop Relat Res"},{"key":"5447_CR25","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/jor.1100070416","volume":"7","author":"SG Hopp","year":"1989","unstructured":"Hopp SG, Dahners LE, Gilbert JA. A study of the mechanical strength of long bone defects treated with various bone autograft substitutes: an experimental investigation in the rabbit. J Orthop Res. 1989;7:579\u201384.","journal-title":"J Orthop Res"},{"key":"5447_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/17453670902804505","volume":"80","author":"M Hirn","year":"2009","unstructured":"Hirn M, de Silva U, Sidharthan S, Grimer RJ, Abudu A, Tillman RM, et al. Bone defects following curettage do not necessarily need augmentation. Acta Orthop. 2009;80:4\u20138.","journal-title":"Acta Orthop"},{"key":"5447_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00264-005-0061-z","volume":"30","author":"LM Jeys","year":"2006","unstructured":"Jeys LM, Suneja R, Chami G, Grimer RJ, Carter SR, Tillman RM. Impending fractures in giant cell tumours of the distal femur: incidence and outcome. Int Orthop. 2006;30:135\u20138.","journal-title":"Int Orthop"},{"key":"5447_CR28","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3928\/01477447-20140225-51","volume":"37","author":"DF Amanatullah","year":"2014","unstructured":"Amanatullah DF, Williams JC, Fyhrie DP, Tamurian RM. Torsional properties of distal femoral cortical defects. Orthopedics. 2014;37:158\u201362.","journal-title":"Orthopedics."},{"key":"5447_CR29","doi-asserted-by":"publisher","first-page":"21319","DOI":"10.1038\/s41598-020-78188-3","volume":"10","author":"A Ghouchani","year":"2020","unstructured":"Ghouchani A, Rouhi G, Ebrahimzadeh MH. Post-operative fracture risk assessment following tumor curettage in the distal femur: a hybrid in vitro and in silico biomechanical approach. Sci Rep. 2020;10:21319.","journal-title":"Sci Rep"},{"key":"5447_CR30","doi-asserted-by":"publisher","first-page":"103360","DOI":"10.1016\/j.compbiomed.2019.103360","volume":"112","author":"A Ghouchani","year":"2019","unstructured":"Ghouchani A, Rouhi G, Ebrahimzadeh MH. Investigation on distal femoral strength and reconstruction failure following curettage and cementation: in-vitro tests with finite element analyses. Comput Biol Med. 2019;112:103360.","journal-title":"Comput Biol Med"},{"key":"5447_CR31","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(13)70277-8","volume":"14","author":"S Chawla","year":"2013","unstructured":"Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013;14:901\u20138.","journal-title":"Lancet Oncol"},{"key":"5447_CR32","doi-asserted-by":"publisher","first-page":"496","DOI":"10.2106\/JBJS.17.00057","volume":"100","author":"C Errani","year":"2018","unstructured":"Errani C, Tsukamoto S, Leone G, Righi A, Akahane M, Tanaka Y, et al. Denosumab may increase the risk of local recurrence in patients with giant-cell tumor of bone treated with curettage. J Bone Joint Surg Am. 2018;100:496\u2013504.","journal-title":"J Bone Joint Surg Am"},{"key":"5447_CR33","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1097\/CORR.0000000000001074","volume":"478","author":"S Tsukamoto","year":"2020","unstructured":"Tsukamoto S, Tanaka Y, Mavrogenis AF, Kido A, Kawaguchi M, Errani C. Is treatment with denosumab associated with local recurrence in patients with giant cell tumor of bone treated with curettage? A systematic review. Clin Orthop Relat Res. 2020;478:1076\u201385.","journal-title":"Clin Orthop Relat Res"},{"key":"5447_CR34","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.3892\/ol.2013.1244","volume":"5","author":"F Mittag","year":"2013","unstructured":"Mittag F, Leichtle C, Kieckbusch I, Wolburg H, Rudert M, Kluba T, et al. Cytotoxic effect and tissue penetration of phenol for adjuvant treatment of giant cell tumours. Oncol Lett. 2013;5:1595\u20138.","journal-title":"Oncol Lett"},{"key":"5447_CR35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/00003086-198501000-00021","volume":"192","author":"PA Jacobs","year":"1985","unstructured":"Jacobs PA, Clemency RE. The closed cryosurgical treatment of giant cell tumor. Clin Orthop Relat Res. 1985;192:149\u201358.","journal-title":"Clin Orthop Relat Res"},{"key":"5447_CR36","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/jso.26397","volume":"123","author":"B Bombardier","year":"2021","unstructured":"Bombardier B, Haase D, Sweeney K, Friedman E, Poppe T, Hughes N. A comparison of depth of necrosis among adjuvant therapies used for the treatment of benign bone tumors. J Surg Oncol. 2021;123:1299\u2013303.","journal-title":"J Surg Oncol"},{"key":"5447_CR37","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/BLO.0b013e318038fc3d","volume":"458","author":"T Pritsch","year":"2007","unstructured":"Pritsch T, Bickels J, Wu CC, Squires HM, Malawer MM. The risk for fractures after curettage and cryosurgery around the knee. Clin Orthop Relat Res. 2007;458:159\u201367.","journal-title":"Clin Orthop Relat Res"},{"key":"5447_CR38","first-page":"E105","volume":"40","author":"RJ Lee","year":"2011","unstructured":"Lee RJ, Mayerson JL, Crist M. Fracture risk with pressurized-spray cryosurgery. Am J Orthop (Belle Mead NJ). 2011;40:E105\u20139.","journal-title":"Am J Orthop (Belle Mead NJ)"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-022-05447-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12891-022-05447-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-022-05447-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T11:24:53Z","timestamp":1652959493000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-022-05447-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["5447"],"URL":"https:\/\/doi.org\/10.1186\/s12891-022-05447-x","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]},"assertion":[{"value":"18 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the guidelines of the Declaration of Helsinki and approved by IRCCS Istituto Ortopedico Rizzoli di Bologna Ethics Committee and Nara Medical University Ethics Committee. Ethics committee approval was not necessary for retrospective studies at National and Kapodistrian University of Athens, School of Medicine. Informed consent was obtained from each participant in IRCCS Istituto Ortopedico Rizzoli and National and Kapodistrian University of Athens, School of Medicine. Nara Medical University Ethics Committee approved a waiver for the informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"477"}}